Kraeber (UK) Ltd
The family owned business, Kraeber & Co GmbH, is an independent, technology based enterprise which was founded on the 1st January 1980 in Hamburg. Hanseatic tradition together with courageous entrepreneurship characterize our company. We are committed to open and global competition which we stand up with our service capabilities. Our emphasis is the development, production, marketing and sales of active pharmaceutical ingredients (APIs) of the highest purity. Kraeber has evolved into a niche marketer and supplier. By continously innovating productions, we became the quality market leader in Europe and in other parts of the world for many of our products.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Company Details
Latest Content from PMHub
NEW PHARMA-EXCLUSIVE WEBINAR: Beyond the Hype; Practical, Compliant AI Solutions for Pharma Engagement
Press Releases | August 27, 2026 | Impetus Digital
See how top-tier pharma teams use compliant AI tools and virtual QIPs to capture real-time market intelligence, confidence scores, and audience insights from live dashboards
Intelligent Commercialization™ across the pharma lifecycle
White Papers and Resources | August 27, 2026 | Inizio
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.
Four steps to a smarter congress strategy: A practical guidebook
White Papers and Resources | August 27, 2026 | Inizio
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.
Real Chemistry Deepens German Market Expertise with Appointment of Dirk Poschenrieder as Managing Director, Germany
Press Releases | August 25, 2026 | Real Chemistry
Senior hire strengthens Real Chemistry’s ability to help healthcare clients connect global strategy to nuanced needs for in-market execution
Cutting the friction from health comms through whole-person design
Press Releases | August 24, 2026 | Mednet
Good design can’t change the reality of illness, remove the pain, or stop the uncertainty. But it can stop learning what comes next from being another burden to carry.
The Future of Decisioning
Press Releases | August 20, 2026 | Havas Lynx
The traditional model for gathering insights is reaching a breaking point. Healthcare Professionals (HCPs) are increasingly time-poor and difficult to reach. Simultaneously, the costs of traditional market research are rising,...
Lucid Group Names Eric Muller as Chief Executive Officer to Lead Next Phase of Growth
Press Releases | August 19, 2026 | Lucid Group Communications Limited
Rick Sannem, outgoing CEO, transitions to Strategic Advisor to the Board
Treating phase 2 study design as a scientific decision is compromising launch performance, warns expert
Press Releases | August 17, 2026 | Nmblr
17th August 2026 – Treating Phase 2 study design solely as a set of scientific decisions, without commercial input, is compromising launch performance, according to Janice MacLennan, founder of Nmblr,...
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Press Releases | August 11, 2026 | Genesis Research Group
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...
Why Modern Dermatology Demands Curiosity Over Precision
Press Releases | August 5, 2026 | Medscape Education
In the high-stakes world of healthcare research and product development, success has long been measured by rigid definitions of precision and predictable trajectories. However, as Dr. Hawa Dumbuya, Director of...